Self Treatment With an Electronic Device for Cognitive Rehabilitation in Patients With Subacute Stroke: A Randomized Controlled Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Stroke
- Sponsor
- Universita di Verona
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Trail Making Test Part A (TMT-A)
- Status
- Terminated
- Last Updated
- 8 months ago
Overview
Brief Summary
The objective of this study is to evaluate whether the independent use of an electronic device by a patient with stroke outcomes can enhance the effectiveness of rehabilitative treatment for attentional functions compared to standard treatment.
Investigators
Valentina Varalta
Doctor
Universita di Verona
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of ischemic or hemorrhagic stroke
- •Within 2 weeks since stroke onset
- •Age under 85 years
- •Attention deficits as measured by the Trails task or the Broken Hearts subtest in the Oxford Cognitive Screen (OCS)
- •Exclusion criteria:
- •Visual impairment documented by clinical history (e.g., cataracts, diabetic retinopathy, glaucoma, hemianopia)
- •Uncompensated psychiatric disorders
- •Drug or alcohol abuse
- •History of dementia
- •Severe comprehension disorders as determined by the Semantics subtest in the Oxford Cognitive Screen (OCS)
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Trail Making Test Part A (TMT-A)
Time Frame: From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment)
The Trail Making Test Part A (TMT-A) is a neuropsychological assessment that measures selective attention and processing speed. Participants connect a series of numbered circles in sequential order as quickly as possible. The score is determined by the time taken to complete the task, with shorter times indicating better performance. Errors may negatively impact the score.
Secondary Outcomes
- Trail Making Test Part B (TMT-B)(From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment))
- Dual task test(From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment))
- short version of the Elithorn's Perceptual Maze Test(From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment))
- Stroop Test(From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment))